Comparative real-world effectiveness and safety of super-bioavailable itraconazole 50 mg bd and 65 mg bd in the management of dermatophytosis

Namrata Mahadkar, Dhiraj S. Dhoot, Hanmant Barkate


In recent times, India has witnessed a steep surge in prescription of itraconazole in the management of dermatophytosis.1 But due to its pharmacokinetics, it has shown multiple variations in the results. To overcome these challenges, a newer itraconazole formulation i.e. super-bioavailable itraconazole (SBITZ) has been launched recently in India. Currently, there are 4 different strengths of SBITZ which are approved by DCGI.2,3 But there is no any clinical data regarding comparison of different strength of SBITZ. This retrospective analysis aimed to compare two different strengths of SBITZ; 50 mg and 65 mg in the management of dermatophytosis.


Itraconazole, Pharmacokinetics, SBITZ

Full Text:



Das S, De A, Saha R, Sharma N, Khemka M, Singh S, et al. The Current Indian Epidemic of Dermatophytosis: A Study on Causative Agents and Sensitivity Patterns. Indian J Dermatol. 2020;65(2):118-22.

Recommendations of the SEC (Dermatology & Allergy) made in its 46th meeting held on 19.06.2020 at CDSCO HQ New Delhi. Available at: Accessed on 24 April 2022.

Recommendations of the SEC (Antimicrobial & Antiviral) made in its 102 and meeting held on 27.07.2021 at CDSCO HQ, New Delhi. Available at: CDSCOWeb/2018/UploadCommitteeFiles/Recommendations%20Antimicrobial%20&%20Antiviral%2027.07.2021.pdf. Accessed on 24 April 2022.

Lozanoc 50 mg Capsules. Available at: Accessed on 27 March 2022.

Highlights of Prescribing Information. Available at: Accessed on 27 March 2022.

Battles Against Fungal Infections Can Leave You Wishing You Had Superpowers. Available at: Accessed on 24 April 2022.

Abuhelwa AY, Foster DJ, Mudge S, Hayes D, Upton RN. Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015;59(9):5681-96.

Thompson GR, Lewis P, Mudge S, Patterson TF, Burnett BP. Open-Label Crossover Oral Bioequivalence Pharmacokinetics Comparison for a 3-Day Loading Dose Regimen and 15-Day Steady-State Administration of SUBA-Itraconazole and Conventional Itraconazole Capsules in Healthy Adults. Antimicrob Agents Chemother. 2020;64(8):e00400-20.

Lindsay J, Sandaradura I, Wong K, Arthur C, Stevenson W, Kerridge I, et al. Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. J Antimicrob Chemother. 2017;72(12):3414-9.

Shenoy M, Dhoot D, Mahajan H, Barkate H. An Open-Label, Randomized, Double-Arm Clinical Trial to Compare the Effectiveness and Safety of Super Bioavailable Itraconazole Capsules and Itraconazole Capsules in the Management of Dermatophytosis in India. Clin Cosmet Investig Dermatol. 2021;14:1367-76.